Reflective of the reliance of prostate cancer on the expression of AR target genes is the observation that over 70 % of CRPC cases harbor AR pathway aberrations, with AR transcriptional activity persisting in the majority of cases of CRPC [31]. The gene discussed is AR; the disease is prostate cancer.